New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 24, 2014
10:03 EDTZFGN, JMP, TRI, MRKT, WHLR, DANG, FDS, EQIX, CECE, CONE, CRMDOn The Fly: Analyst Downgrade Summary
Today's noteworthy initiations include: CECO Environmental (CECE) initiated with a Buy at Canaccord... CorMedix (CRMD) initiated with a Buy at Roth Capital... CyrusOne (CONE) initiated with an Equal Weight at Barclays... Dangdang (DANG) initiated with a Buy at Citigroup... Equinix (EQIX) initiated with an Equal Weight at Barclays... FactSet (FDS) initiated with a Buy at Jefferies... JMP Group (JMP) initiated with an Outperform at Barrington... Markit (MRKT) initiated with a Hold at Jefferies... Thomson Reuters (TRI) initiated with a Hold at Jefferies... Wheeler REIT (WHLR) initiated with a Buy at Maxim... Zafgen (ZFGN) initiated with an Outperform at Leerink.
News For CECE;CRMD;CONE;DANG;EQIX;FDS;JMP;MRKT;TRI;WHLR;ZFGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 21, 2015
11:01 EDTTRIBroadridge to acquire Fiduciary Services unit from Thomson Reuters
Subscribe for More Information
09:58 EDTEQIXOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:49 EDTEQIXEquinix downgraded to Hold from Buy at Gabelli (pre--open)
Subscribe for More Information
06:29 EDTEQIXEquinix downgraded to Hold from Buy at Stifel
Stifel downgraded Equinix to Hold based on valuation and lack of catalysts.
May 20, 2015
08:04 EDTEQIXEquinix receives favorable REIT private letter ruling from IRS
Subscribe for More Information
May 19, 2015
14:44 EDTCRMDCourt finds TauroPharm infringed CorMedix patent, utility models
In a regulatory filing earlier, CorMedix announced that it has received written copies of the May 8 decisions of the District Court of Mannheim on CorMedix's patent and utility model infringement cases in Germany related to Neutrolin. The written decisions confirm that the two proceedings brought by CorMedix against TauroPharm have been stayed. The court found that the commercialization by TauroPharm in Germany of its TauroLock catheter lock solutions Hep100 and Hep500 infringes both CorMedix’s patent and utility model, and further that there is no prior use right that would allow TauroPharm to continue to make, use or sell its product in Germany. However, the court declined to issue an injunction based on the likelihood that the European Patent Office, in the case of the patent, or the German Patent and Trademark Office, in the case of the utility model, may find that the patent or utility model is invalid. The court noted the possible publication of certain instructions for product use that may be deemed to constitute prior art. As such, the court will defer consideration of injunction until the EPO or German PTO rules on the underlying validity of the patent/utility model. CorMedix continues to believe that the patent and utility model validly claims inventions.
May 18, 2015
15:19 EDTWHLRWheeler REIT buys Sunshine Shopping Plaza for $10.35M
Subscribe for More Information
May 15, 2015
17:15 EDTEQIXPaulson & Co. gives quarterly update on stakes
Subscribe for More Information
08:56 EDTTRIReuters, Xinhua discuss deeper cooperation, Xinhua reports
Subscribe for More Information
May 14, 2015
07:21 EDTMRKTMarkit management to meet with UBS
Subscribe for More Information
May 13, 2015
07:27 EDTMRKTMarkit files to sell 3.84M shares of common stock for holders
Subscribe for More Information
07:03 EDTMRKTMarkit reports Q1 adjusted EPS 36c, consensus 36c
Subscribe for More Information
May 12, 2015
16:47 EDTWHLRWheeler REIT reports Q1 core FFO (9c), consensus (9c)
Subscribe for More Information
16:03 EDTZFGNZafgen reports Q1 EPS (53c), consensus (65c)
"With enrollment progressing well in our Phase 2b trial in patients with severe obesity complicated by type 2 diabetes, we remain on track to release important six month interim data in late 2015 or very early 2016. The ZAF-203 trial will provide our first look at the effects of beloranib treatment on both body weight and glycemic control in the setting of type 2 diabetes, an important and difficult to treat co-morbidity of obesity," said Dr. Dennis Kim, Chief Medical Officer of Zafgen. As of March 31, the company had cash and cash equivalents and marketable securities totaling $234.2M.
15:00 EDTMRKTNotable companies reporting before tomorrow's open
Subscribe for More Information
07:52 EDTZFGNLeerink to hold a tour
Subscribe for More Information
07:11 EDTFDSFactSet raises dividend by 13% to 44c per share from 39c per share
Subscribe for More Information
May 11, 2015
09:49 EDTEQIXInterXion could become takeover target, Ben Harrington says
Subscribe for More Information
08:24 EDTEQIXEquinix and Global Capacity announce collaboration
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use